CMO Industry Growth Unsustainable According to Report
PTSM: Pharmaceutical Technology Sourcing and Management
PharmSource forecasts slow growth in a new report on the outlook for the contract manufacturing industry.
A report published on Sept. 1, 2015 by PharmSource states that, despite an increase in the number of product approvals, growth of the bio/pharmaceutical contract manufacturing sector is projected to slow down. The report states that shrinking product volumes, fewer opportunities for facility acquirement, increasing efforts to control drug costs, and high levels of capital investment by biopharma companies are contributing to the slow growth.
PharmSource states that the contract dose manufacturing industry generated $16.8 billion in revenues for 2014, due in part by the acquisition of facilities. Out of 221 companies, 16 account for 50% of industry revenue. According to the PharmSource, however, “although contract manufacturing of bio/pharmaceutical finished dose forms grew at twice the rate of the overall industry during the 2012–2014 period, contract manufacturing organizations (CMOs and CDMOs) and their investors should be alerted that recent growth rates are unlikely to be sustainable.”
Source: PharmSource
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
